Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited...

Cardiac catheterization remains the gold standard for the diagnosis and management of pediatric pulmonary hypertension (PH)...

Pulmonary arterial hypertension (PAH) is driven by pathologies associated with increased metabolism such as pulmonary revascularization, vasoconstriction and smooth muscle cell proliferation in pulmonary artery wall...

Reduced exercise capacity in pulmonary hypertension (PH) significantly impacts quality of life...

Pulmonary thromboembolism caused by thrombi blocking major pulmonary artery and its branches, is a frequently encountered phenomenon and an important cause of high morbidity and mortality in lung diseases and may develop into persistent pulmonary hypertension (PH)...

Right ventricular (RV) dysfunction in pulmonary arterial hypertension (PAH) is associated with poor outcomes...

In this Community Call, we discussed: 

• Pericytes contribute to pulmonary vascular remodeling via HIF2α signaling 
• Advanced hemodynamic and cluster analysis for identifying novel RV function subphenotypes in patients with pulmonary hypertension

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and critical malignancy-related disease characterized by acute progressive pulmonary hypertension (PH).In most cases of PTTM, the cancer can be diagnosed in advance...

AV-101 (imatinib) powder for inhalation, an investigational dry powder inhaled formulation of imatinib designed to target the underlying pathobiology of pulmonary arterial hypertension, was generally well tolerated in healthy adults in a phase 1 single...